Citing Costs, Scotland Regulators Reject Adding Orkambi and Symkevi to National Health System
The Scottish Medicines Consortium (SMC) is recommending against bringing two of Vertex Pharmaceuticals’ approved cystic fibrosis (CF) treatments — Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) — into routine use by adding them to the country’s national health system. Each treatment’s “cost in relation to its health…